期刊文献+

低分子肝素相对分子质量测定用对照品的研制 被引量:3

Study on the preparation of relative molecular mass calibrator for low molecular mass heparin
原文传递
导出
摘要 目的:制备类似WHO的附带一宽分布标样表的低分子肝素(low molecular weight heparin,LMWH)相对分子质量测定用对照品。方法:采用肝素酶Ι控制降解肝素得到宽分布低分子的肝素片段混合物,并以WHO LMWH相对分子质量对照品为对照,采用高效分子排阻色谱法绘制自制相对分子质量与累积面积百分比的量表。分别利用该自制对照品与WHO对照品检测4种不同工艺制备的LMWH相对分子质量。结果:自制LMWH相对分子质量对照品与WHO相对分子质量对照品的校正曲线基本重合在一起,2种对照品测定的4种LMWH相对分子质量结果十分接近。结论:自制的LMWH相对分子质量测定用对照品可以用于LMWH相对分子质量的测定,为LMWH相对分子质量测定用对照品国产化奠定了基础。 Objective: To establish a relative molecular mass calibrator with a broad standard table for low molecu- lar mass heparin (LMWH). Methods: LMWH relative molecular mass calibrator with broad distribution was pro- duced through controlled degradation of heparin sodium by heparinase I. With the WHO calibrator as the reference standard, a broad standard table for the prepared calibrator was constructed by high performance size exclusive chro- matography (HPSEC). To evaluate the feasibility of the latter, molecular mass profiles of four LMWHs obtained with different methods were determined by WHO LMWH calibrator and the prepared calibrator. Results: The calibration curves of the prepared calibrator coincided with the WHO calibrator in general. Relative molecular mass of LMWHs determined by the prepared calibrator agreed well with that of the WHO calibrator. Conclusion: The prepared cali- brator was suitable for routine quality control of molecular mass determination for commercial LMWH products.
出处 《药物分析杂志》 CAS CSCD 北大核心 2012年第11期1976-1980,2001,共6页 Chinese Journal of Pharmaceutical Analysis
基金 十一五"重大新药创制"项目(2008ZX09504)
关键词 低分子肝素 宽分布 相对分子质量 对照品研制 高效分子排阻色谱 low molecular mass heparin broad distribution relative molecular mass calibrator high performance size exclusive chromatography(HPSEC)
  • 相关文献

参考文献13

  • 1Van Dedem G. Collaborative assay of heparin molecular weights by high performance size exclusion chromatography. Report, Diosynth BV, Oss, The Netherlands, 1985.
  • 2Sugisaka N,Petrasek FJ. Rapid molecular size characterization of hep- arins by high pressure liquid chromatography. Fed Proc, 1977,36 : 89.
  • 3Harenberg J, Jan X, Vries DE. Characterization of heparins by high performance size exclusion liquid chromatography. J Chromatogr A, 1983.261,287.
  • 4Muller D, Ndoume, Jozefonvicz. High - pressure size - exclusion chro- matography of anticoagulant materials. J Chromatogr A, 1984,297:351.
  • 5杜姗姗,崔慧斐.低分子肝素相对分子质量测定方法[J].药物分析杂志,2011,31(2):402-407. 被引量:2
  • 6吕志华,于广利,赵峡,徐家敏.不同标准品对HPGPC法测定多糖相对分子质量的影响[J].中国新药杂志,2002,11(3):220-221. 被引量:18
  • 7Jeske W, Ahsan A, Fareed J. Molecular weight profiling of low molec- ular weight heparins utilizing a heparinase degraded oligosaccharide mixture as a calibrator. Thromb Res, 1993,70 (1) :39.
  • 8Mulloy B, Gee C, Wheeler SF, et al. Molecular weight measurements of low molecular weight heparins by gel permeation chromatography. J Thromb Haemost,1997,77 (4) :668.
  • 9Mulloy B, Heath A, Emmanulle M, et al. A collaborative study to es- tablish the 2nd intermational standard low molecular weight heparin for molecular weight calibration. Expert Committee on Biological Standardization, Geneva, 2007.
  • 10曹苹,张麟生.低分子肝素的抗凝与抗血栓作用[J].中国医院药学杂志,2001,21(5):289-291. 被引量:38

二级参考文献44

  • 1姬胜利,张天民.肝素与低分子肝素的研究进展[J].中国生化药物杂志,1996,17(5):216-219. 被引量:33
  • 2卫生部医政司.全国临床检验操作规程(第1版)[M].南京:东南大学出版社,1992.24.
  • 3国家药典委员会.中国药典(二部)临床用药须知:2000年版[M].北京:化学工业出版社,2001.411.
  • 4.英国药典[S].2002年版[M].,2002.443,731,560,1024,1125,1505.
  • 5[1]Xue CH,Yu GL,Takashi H,et al.Antioxidative activities of seve ral marine polysaccharides evaluated in a phosphatidylcholine-liposomal suspens ion and organic solvents[J].Biosci Biotechnol Biochem,1998,62(2)∶206-210 .
  • 6[2]Hyun OY,Nur SG,Toshihiko T,et al.Preparation and structural determi nation of dermatan sulfate-derived ologosaccharides[J].Glycobiology, 2000,10(10)∶1033-1037.
  • 7[4]British Pharmacopoeia CD.Low-Molcular-Weight-Heparins[S].1998(Versio n2.0)[s.l.]:stationary office Ltd,1998.606-608.
  • 8Liu YG,Bo SQ,Zhu YJ,et al.Determination of molecular weight and molecular sizes of polymers by high temperature gel permeation chromatography with a static and dynamic laser light scattering detector.Polymer,2003,44(23):7209.
  • 9CHEN Hui-li(陈惠黎),WANG Ke-yi(王克荑).Glycoconjugates Structrue and Fuction(糖复合物结构与功能).Shanghai(上海):Shanghai Medicin University Press(上海医科大学出版社),1997.43.
  • 10McNeal CJ,Macfarlane RD,Jardine I.A novel mass spectrometric procedure to rapidly determine the partial structure of heparin fragments.Biochem Biophys Res Commun,1986,139(1):18.

共引文献83

同被引文献19

  • 1国家食品药品监督管理局药品审评中心.关于药品注册管理的补充规定[EB/OL].(2003-12-23)[2014-04-10].http://www.cde.org.cn/news.do?method=largelnfo&id=84.
  • 2陆益红,赵慧玲,余立,等.关于低分子量肝素类药品的审评思考[EB/OL](2010-11-15)[2014-04-10].http;//www. cde. org. cn/dzkw, do? method = largePage&id = 311935.
  • 3Food and Drug Administration. Citizenpetion response [ EB/OL ]. (2010-07 -23) [2014 -04 - 10]. http://www, fda. gov/ downloads/Drugs/DrugSafety/PostmarketDrugSafetylnformationfo- rPatients andProviders/UCM220083, pdf.
  • 4Food and Drug Administration. Draft guidance on enoxaparin so- dium [ EB/OL]. (2015 - 50) [ 2054 -04 - 10 ]. http ://www. fda. gov/downloads/Drugs/GuidanceComp5ianceRegulatory5nformation/ Guidances/UCM277709. pdf.
  • 5Committee for Medicinal Products for Human ( CHMP). Guide- line on non-clinical and clinical development of similar biological medicinal products containing low moleeular-weight-heparins [EB/OL]. (2013 -01 - 17) [2014 -04 - 10]. http://www. ema. europa, eu/docs/en _ GB/document _ library/Scientific _ guideline/2013/01/WC500138309, pdf.
  • 6国家食品药品监督管理局药品审评中心.多组分生化药注射剂基本技术要求(试行)[EB/OL].(2008-01-10)[2014-04 - 10 ]. http://www, cde. org. cn/zdyz, do? method = largePage &id = 113.
  • 7国家药品审评中心化药临床二部.关于仿制的低分子肝素类产品新增技术要求的意见[EB/OL].(2013-11-25)[2014-04 -101. http://www, cde. org. cn/dzkw, do? method = largePage &id = 313254.
  • 8European Medicines Agency. Similar biological medicinal prod- ucts containing biotechnology-derived proteins as active sub- stance : non-clinical and clinical issues[ EB/OL]. (2013 - 06 - 03) [2014 - 04 - 10]. http://www, ema. europa, eu/docs/en GB/document_library/Scientific_guideline/2013/O6/WC500144124. Ddf.
  • 9Food and Drug Administration. Scientific Considerations in dem- onstrating biosimilarity to a reference product[ EB/OL]. (2012 - 02) [ 2014 - 04 - 10 ]. http://www, fda. gov/downloads/Drugs/ Gui pdf, oryInformation/Guidances/UCM291128.
  • 10Roger D. Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events: US, 5389618[P]. 1995-02-14.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部